Pharmacokinetic Optimisation in the Treatment of Parkinson's Disease: An Update

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.45, Iss.2, 2006-01, pp. : 109-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson's Disease

By Contin M. Riva R. Albani F. Baruzzi A.

CNS Drugs, Vol. 14, Iss. 6, 2000-12 ,pp. : 439-455

Adis International

Access to resources Recommend Favorite

The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease

By Tábi Tamás Szökő Éva Vécsei László Magyar Kálmán

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 5, 2013-05 ,pp. : 629-636

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic Optimisation of the Treatment of Neurocysticercosis

By Sotelo J. Jung H.

Clinical Pharmacokinetics, Vol. 34, Iss. 6, 1998-06 ,pp. : 503-515

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease

By Deleu D.

Clinical Pharmacokinetics, Vol. 41, Iss. 4, 2002-01 ,pp. : 261-309

Adis International

Access to resources Recommend Favorite

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

By Müller Thomas

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1015-1024

Informa Healthcare

Access to resources Recommend Favorite